Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the quarter’s ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Supernus CEO Jack Khattar said the deal adds a “significant fourth growth product to our portfolio and further diversifies ...

Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing.

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...

Check out our SUPN stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.